DUBLIN--(BUSINESS WIRE)--Aug 10, 2018--The "Rheumatoid Arthritis: Update Bulletin #3" newsletter has been added to ResearchAndMarkets.com's offering.

Business Questions

How do KOLs perceive Boehringer Ingelheim's adalimumab biosimilar, Cyltezo? With three adalimumab biosimilars now approved in Europe, what concerns do prescribers have with regard to multiple biosimilar versions becoming available? How do KOLs view Sandoz's Rixathon, the second rituximab biosimilar to enter the RA space in Europe? Celltrion is currently developing a subcutaneously administered infliximab biosimilar, but what need is there currently for a subcutaneous version of this product? What concerns might prescribers have regarding Celltrion's subcutaneous infliximab biosimilar?

For more information about this newsletter visit https://www.researchandmarkets.com/research/23smds/rheumatoid?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180810005178/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Allergy and Immunology

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/10/2018 07:43 AM/DISC: 08/10/2018 07:43 AM

http://www.businesswire.com/news/home/20180810005178/en